Protalix BioTherapeutics (PLX) Shares Outstanding (2010 - 2026)

Protalix BioTherapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $80.6 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 1.21% year-over-year to $80.6 million in Q1 2026; TTM through Mar 2026 was $80.6 million, a 1.21% increase from a year earlier, with the FY2025 full-year figure at $80.4 million, up 6.03% from the prior year.
• Shares Outstanding (Entity) was little changed at $80.6 million in Q1 2026 per PLX's latest filing, from $80.4 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $80.6 million in Q1 2026 and bottomed at $47.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $73.3 million (2024), against an average of $69.5 million.
• Across the five-year window, Shares Outstanding (Entity) surged 43.99% in 2023 and rose 0.93% in 2024, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $53.8 million in 2022, then surged by 35.62% to $73.0 million in 2023, then increased by 3.97% to $75.9 million in 2024, then gained by 6.03% to $80.4 million in 2025, then grew by 0.18% to $80.6 million in 2026.
• Per Business Quant, the three latest PLX Shares Outstanding (Entity) figures stand at $80.6 million (Q1 2026), $80.4 million (Q4 2025), and $80.4 million (Q3 2025).